Figure 6.
Comparison of certolizumab pegol (CZP) with placebo for active ankylosing spondylitis (AS) patients in terms of ACR70 response rate.
Comparison of certolizumab pegol (CZP) with placebo for active ankylosing spondylitis (AS) patients in terms of ACR70 response rate.